Strategic priorities for respiratory syncytial virus (RSV) vaccine development

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Anderson, L J ^a   Dormitzer, P R ^b   Nokes, D J ^c,d   Rappuoli, R ^e   Roca, A ^f   Graham, B S ^g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Novartis Vaccines and Diagnostic   (United States)

^c KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^f MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Global health priorities; Respiratory syncytial virus; Vaccines

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS VECTOR;

ADULT DISEASE; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PARAINFLUENZA VIRUS 3; PREGNANT WOMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRUS TRANSMISSION;

AGED; BIOMEDICAL RESEARCH; CHILD; FEMALE; HUMANS; INFANT; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VIRAL FUSION PROTEINS;

EID: 84876735541     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.106     Document Type: Review

References (42)

1. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
2. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
3. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among U.S. children, 1980-1995. JAMA 1999, 282:1440-1447.
4. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239:149-166.
5. Hurwitz J.L. Respiratory syncytial virus vaccine development. Expert Rev Vaccines 2011, 10:1415-1433.
6. van Bleek G.M., Osterhaus A.D., de Swart R.L. RSV 2010: recent advances in research on respiratory syncytial virus and other pneumoviruses. Vaccine 2011, 29:7285-7291.
7. Chang J. Current progress on development of respiratory syncytial virus vaccine. BMB Reports 2011, 44:232-237.
8. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162:80-99.
9. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543-546.
10. Nokes D.J., Okiro E.A., Ngama M., Ochola R., White L.J., Scott P.D., et al. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya. Clin Infect Dis 2008, 46:50-57.
11. Cox M.J., Azevedo R.S., Cane P.A., Massad E., Medley G.F. Seroepidemiological study of respiratory syncytial virus in Sao Paulo state, Brazil. J Med Virol 1998, 55:234-239.
12. Henderson F.W., Collier A.M., Clyde W.A., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979, 300:530-534.
13. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
14. Sommer C., Resch B., Simoes E.A. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 2011, 5:144-154.
15. Stockman L.J., Curns A.T., Anderson L.J., Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012, 31:5-9.
16. Crowe J.E., Williams J.V. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev 2003, 4:112-119.
17. O'Callaghan-Gordo C., Bassat Q., Morais L., Diez-Padrisa N., Machevo S., Nhampossa T., et al. Etiology and epidemiology of viral pneumonia among hospitalized children in rural Mozambique: a malaria endemic area with high prevalence of human immunodeficiency virus. Pediatr Infect Dis J 2011, 30:39-44.
18. Robertson S.E., Roca A., Alonso P., Simoes E.A., Kartasasmita C.B., Olaleye D.O., et al. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bull World Health Organ 2004, 82:914-922.
19. Madhi S.A., Schoub B., Simmank K., Blackburn N., Klugman K.P. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000, 137:78-84.
20. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969, 89:449-463.
21. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization: I. A field of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969, 89:435-448.
22. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
23. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
24. Wu P., Hartert T.V. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther 2011, 9:731-745.
25. Groothuis J.R., Simoes E.A.F., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J., et al. Prophylactic administration of respiratory syncytial virus immune globulin in high-risk infants and young children. N Engl J Med 1993, 329:1524-1530.
26. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98:708-715.
27. Lamprecht C.L., Krause H.E., Mufson M.A. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1981, 134:211-217.
28. Stensballe L.G., Ravn H., Kristensen K., Agerskov K., Meakins T., Aaby P., et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009, 123:398-403.
29. Acedo L., Diez-Domingo J., Morano J.A., Villanueva R.J. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications. Epidemiol Infect 2010, 138:853-860.
30. Belshe R.B., Newman F.K., Anderson E.L., Wright P.F., Karron R.A., Tollefson S., et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 2004, 190:2096-2103.
31. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005, 191:1093-1104.
32. Luongo C., Yang L., Winter C.C., Spann K.M., Murphy B.R., Collins P.L., et al. Codon stabilization analysis of the 248 temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine 2009, 27:5667-5676.
33. Belshe R.B., Van Voris L.P., Mufson M.A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 1982, 145:311-319.
34. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
35. Feltes T.F., Sondheimer H.M., Tulloh R.M., Harris B.S., Jensen K.M., Losonsky G.A., et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011, 70:186-191.
36. Bernstein D.I., Malkin E., Abughali N., Falloon J., Yi T., Dubovsky F. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012, 31:109-114.
37. Waris M.E., Tsou C., Erdman D.D., Day D.B., Anderson L.J. Priming with live respiratory syncytial virus (RSV) prevents enhanced pulmonary inflammatory responses associated with formalin inactivated RSV immunization in BALB/c mice. J Virol 1997, 71:6935-6939.
38. Falsey A.R., Walsh E.E., Capellan J., Gravenstein S., Zambon M., Yau E., et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008, 198:1317-1326.
39. Groothuis J., King S., Hogerman D., Paradiso P., Simoes E. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998, 177:467-469.
40. Anderson R., Huang Y., Langley J.M. Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol 2010, 5:585-602.
41. Radu G.U., Caidi H., Miao C., Tripp R.A., Anderson L.J., Haynes L.M. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol 2010, 84:9632-9636.
42. Weber M.W., Milligan P., Hilton S., Lahai G., Whittle H., Mulholland E.K., et al. Risk factors for severe respiratory syncytial virus infection leading to hospital admission in children in the Western Region of The Gambia. Int J Epidemiol 1999, 28:157-162.